Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mullan

Showing results (141-150 of 142) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 142 results.
BMJ Open|July 21, 2016
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flowOlga Meulenbroek, Sarah O'Dwyer, Daan de Jong, et al.
Plos Medicine|September 25, 2018
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trialBrian Lawlor, Ricardo Segurado, Sean Kennelly, et al.
Pageof 15

Showing results (141-150 of 142) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 142 results.
BMJ Open|July 21, 2016
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flowOlga Meulenbroek, Sarah O'Dwyer, Daan de Jong, et al.
Plos Medicine|September 25, 2018
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trialBrian Lawlor, Ricardo Segurado, Sean Kennelly, et al.
Pageof 15